JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

Home・Aktien・Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

23.85 -1.93

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

23.79

Max

24.47

Schlüsselkennzahlen
By Trading Economics
Einkommen	50M -42M
Verkäufe	4.6M 171M
Gewinnspanne	-24.594
Angestellte	705
EBITDA	40M -40M

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+50.48% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	4. Nov. 2025

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	700M 3.1B
Vorheriger Eröffnungskurs	25.78
Vorheriger Schlusskurs	23.85

Nachrichtenstimmung

By Acuity

73%

27%

348 / 374 Ranking in Healthcare

Apellis Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

11. Aug. 2025, 17:49 UTC

Wichtige Markttreiber

180 Life Sciences Stock Jumps on $156 Million Notes Sale

11. Aug. 2025, 17:18 UTC

Wichtige Markttreiber

Tiziana Life Sciences Rises After FDA Approves IND for Foralumab Trial

11. Aug. 2025, 16:25 UTC

Ergebnisse

Correction to Constellation Software 2Q Revenue Rises, Profit Shrinks Article on Aug. 8

11. Aug. 2025, 23:50 UTC

Market Talk

Nikkei May Rise as Yen Weakens -- Market Talk

11. Aug. 2025, 23:42 UTC

Market Talk

Global Energy Roundup: Market Talk

11. Aug. 2025, 23:42 UTC

Market Talk

Woodside's Share Price Implies Lofty Oil Price -- Market Talk

11. Aug. 2025, 23:36 UTC

Market Talk

Gold Edges Higher on Likely Technical Recovery -- Market Talk

11. Aug. 2025, 23:32 UTC

Market Talk

Argosy's New Bull Sees Sentiment Toward REITs Improving -- Market Talk

11. Aug. 2025, 23:02 UTC

Market Talk

RBA Set to Lower OCR With New Forecasts in Focus -- Market Talk

11. Aug. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

11. Aug. 2025, 20:37 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

Bakkt Holdings: Andy Main Will Step Dn as Co-CEO and Director, Effective Aug 11, and Akshay Naheta Will Assume Role of CEO >BKKT

11. Aug. 2025, 20:37 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

Bakkt Holdings 2Q Rev $577.9M >BKKT

11. Aug. 2025, 20:37 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

Bakkt Holdings: In Upcoming Qtr, Will Conduct Comprehensive Review of Cost Structure to Ensure We Are Optimized, Driving Synergies Across Business, and Accelerating Path to Profitability >BKKT

11. Aug. 2025, 20:22 UTC

Ergebnisse

Exodus Movement: Assets 2,058 Units of Bitcoin Valued at $220.5M, 2,729 Units of Ether Valued at $6.8M, $58.1M in Cash and Cash Equivalents, USD Coin, Treasury Bills as of June 30 >EXOD

11. Aug. 2025, 20:22 UTC

Ergebnisse

Exodus Movement: Monthly Active Users 1.5M at End 2Q, Unchanged From 1.5M as of June 30, 2024 >EXOD

11. Aug. 2025, 20:22 UTC

Ergebnisse

Exodus Movement: Processed Volume $1.38B in 2Q Dn 37% From 1Q, Bitcoin, Tether (TRX Network), Tether (ETH Network), USDC, SOL Top Assets Traded in 2Q >EXOD

11. Aug. 2025, 20:22 UTC

Ergebnisse

Exodus Movement: Digital Assets and Liquid Assets $291.2M >EXOD

11. Aug. 2025, 20:22 UTC

Ergebnisse

Exodus Movement 2Q Rev $25.8M >EXOD

11. Aug. 2025, 20:14 UTC

Market Talk

Canada Dollar Faces Near-Term Weakness on Trade Row, September Rate-Cut Chatter -- Market Talk

11. Aug. 2025, 19:12 UTC

Market Talk

Crude-Oil Futures Edge Up in Rangebound Trade -- Market Talk

11. Aug. 2025, 18:56 UTC

Market Talk

U.S. Natural-Gas Futures Fall on Forecast Loss of Late August Heat -- Market Talk

11. Aug. 2025, 18:31 UTC

Market Talk

Mining Halt Could Lift Lithium Prices in Near Term -- Market Talk

11. Aug. 2025, 17:43 UTC

Market Talk

Freeport-McMoRan Can Push Up Prices, Profits With Copper Tariff Protection -- Market Talk

11. Aug. 2025, 17:28 UTC

Market Talk

Crossborder Trade Tensions Accelerate Softness in Canada Rents -- Market Talk

11. Aug. 2025, 17:16 UTC

Market Talk

Commodity Longs Fall to 11-Month Low -- Market Talk

11. Aug. 2025, 16:42 UTC

Akquisitionen, Fusionen, Übernahmen

Adobe Stock Gets a Downgrade. 'AI Is Eating Software,' Analyst Says. -- Barrons.com

11. Aug. 2025, 16:27 UTC

Akquisitionen, Fusionen, Übernahmen

BBVA Says Sabadell Offer Remains in Effect

11. Aug. 2025, 16:26 UTC

Akquisitionen, Fusionen, Übernahmen

BBVA Previously Said It Won't Withdraw Offer to Buy Sabadell

11. Aug. 2025, 16:25 UTC

Akquisitionen, Fusionen, Übernahmen

Banco de Sabadell Announced TSB Sale on July 1

11. Aug. 2025, 16:25 UTC

Akquisitionen, Fusionen, Übernahmen

Banco de Sabadell Shareholders Approved TSB Unit Sale on Aug 6

Peer-Vergleich

Kursveränderung

Apellis Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

50.48% Vorteil

12-Monats-Prognose

Durchschnitt 35.89 USD 50.48%

Hoch 60 USD

Tief 19 USD

Basierend auf 19 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Apellis Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

19 ratings

Buy

Halten

Sell

Basierend auf 19 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Apellis Pharmaceuticals Inc – Dist abgegeben haben.

Stimmung

By Acuity

348 / 374 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.